{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "TSHA",
  "name": "Taysha Gene Therapies, Inc.",
  "url": "https://frontierpicks.com/dossiers/TSHA/",
  "json_url": "https://frontierpicks.com/dossiers/TSHA.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "MEDIUM",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Clinical binary printed clean (2026-06-22: 100% milestone response N=12, zero treatment-related SAEs) but the next catalyst slipped to H1 2027 — pivotal six-month interim AND FDA BLA-pathway feedback both guided to the first half of next year. Stock is pinned at ~$5.96 under its $6.00 June offering price with ~3 quarters of empty calendar ahead. De-risked asset, absent trade.",
  "invalidation_trigger": "A weekly close below $5.25 loses the post-offering consolidation floor and turns placement digestion into distribution. Secondary: a further slip in the H1 2027 pivotal interim guidance at the Q2 print, an FDA demand for a randomized/sham-controlled pivotal, or any treatment-related SAE or DLT in the pivotal/ASPIRE cohorts.",
  "catalyst_date": null,
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-06-24",
  "invalidation_fired": false,
  "themes": [
    "rare-disease-gene-therapy",
    "precision-biotech-therapeutics",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-06-22: the defining clinical binary printed CLEAN — REVEAL Part A 12-month data showed 100% response (N=12), 310 functional gains deepening over time, zero treatment-related SAEs/DLTs. The major de-risking catalyst is now behind the stock, not ahead of it.",
    "2026-06-24: dilution-into-strength executed — $200M offering priced at $6.00 (32.5M shares + 833,333 pre-funded warrants at $5.999); ~9.2% after-hours drop. The prior watch flag (opportunistic S-3/ATM into a data rally) has now triggered; overhang is the absorption of new shares near $6.",
    "Pre-revenue clinical-stage: no product revenue line. Valuation is entirely approval-probability-weighted TSHA-102, a single asset in a single indication.",
    "Primary endpoint is a novel scale (Rett Syndrome Developmental Milestone Assessment) in an open-label single-arm design; the FDA can still request controlled data at review.",
    "Share count 325.3M after the June 2026 follow-on ($230M gross, full underwriter option exercised at a $6.00 base deal price). Dilution history is heavy — check the latest cover-page count.",
    "Cash $455.4M at 2026-06-30 with runway guided into 2H 2028. An opportunistic ATM priced below $6.00 would contradict that guidance.",
    "Post-2026-08-03, commercial manufacturing depends on one Catalent facility (Harmans, MD). Single-site CMC concentration until a second source is disclosed.",
    "Coverage is Strong Buy-skewed with August 2026 aggregator targets clustering ~$10.80-$13.25; these are risk-adjusted approval NPVs, not tape-supported levels."
  ],
  "body_markdown": "\n> Sources: [Q2 2026 results (2026-08-11)](https://www.globenewswire.com/news-release/2026/08/11/3343130/0/en/taysha-gene-therapies-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html) · [Taysha–Catalent commercial supply agreement (2026-08-03)](https://www.globenewswire.com/news-release/2026/08/03/3337427/0/en/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial-manufacturing-support-of-tsha-102-gene-therapy-for-rett-syndrome.html) · [Catalent release (2026-08-03)](https://www.catalent.com/news/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-future-commercial) · [REVEAL pivotal dosing complete (2026-06-22)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-completion-dosing-reveal-pivotal/) · [stockanalysis.com quote page](https://stockanalysis.com/stocks/tsha/)\n\n## TSHA — Taysha Gene Therapies, Inc.\n\n## Current Thesis\n\nThe frame set out in the prior note has not changed; the Q2 print on 2026-08-11 confirmed it and closed the financing question inside it. Topline data from the REVEAL pivotal six-month interim **and** FDA feedback on the BLA submission pathway remain guided to **the first half of 2027**. PPQ manufacturing completion remains guided to **Q4 2026**. Nothing in the quarter pulled either date forward.\n\nWhat did change is the balance sheet and the commercial plumbing. Cash and cash equivalents stood at **$455.4M at 2026-06-30**, with runway guided **into the second half of 2028 and through potential BLA approval** — the June follow-on closed at **$230M gross** after full exercise of the underwriter option, versus the $200M base deal priced at $6.00 on 2026-06-24. Share count is **325.3M**. On 2026-08-03 Catalent was named primary commercial manufacturer for TSHA-102 at its FDA-licensed commercial gene therapy facility in Harmans, Maryland, extending a supply relationship that dates to 2020.\n\nPrice has done nothing with any of it. The last completed daily close was **$5.95 (2026-08-14)**, still under the $6.00 June placement price roughly seven weeks after the deal, **-14.8%** from the $6.98 52-week high on the adjusted series, with a **3-month return of -0.2%** and **RSI(14) at 57.2**. A clean pivotal-enrolment print, a fully funded runway and a commercial-supply agreement have produced a flat quarter. That is the shape of a narrative that has already been priced for what is known and has nothing dated left to trade against until 2027.\n\n**The narrative is maturing.** The de-risking headline (2026-06-22 Part A durability, 100% milestone response) is behind the stock. Coverage is established and Strong Buy-skewed, participation has stopped expanding, and the 2026-08-11 update produced no guidance change and no re-rating. It is not saturated — the structure is intact and the base is holding above the June deal digestion zone — but the fresh-attention leg ended in late June.\n\n## Bull Case\n\n- **2026-08-11 — funded through the decision.** $455.4M cash at 2026-06-30, runway guided into 2H 2028 and through potential BLA approval. Q2 R&D $38.6M and G&A $12.1M frame the burn against that balance. The financing overhang that normally sits on a pre-revenue gene-therapy name ahead of a filing is, on company guidance, resolved.\n- **2026-08-03 — commercial manufacturing locked.** Catalent named primary commercial manufacturer post-approval, at an FDA-licensed commercial gene therapy site (Harmans, MD), with capacity secured ahead of a potential launch. Gene-therapy BLAs fail on CMC as often as on efficacy; securing commercial capacity a year before a filing decision is a dated step toward that gate rather than a press release about intent.\n- **2026-08-11 — safety record extended.** No severe treatment-related serious adverse events and no dose-limiting toxicities across **33 patients treated** to date. For intrathecal AAV9, a clean cumulative safety database across a full pivotal cohort is the load-bearing element of the single-arm pathway.\n- **2026-06-22 / reiterated 2026-08-11 — efficacy margin over the agreed bar.** 100% milestone response at 12 months in the N=12 Part A cohort against an FDA-aligned **33% efficacy threshold**. The gap between observed response and the pre-agreed bar is what makes an interim-driven filing plausible.\n- **2026-06-22 — registrational cohorts fully dosed.** 17 patients in REVEAL pivotal, 4 in ASPIRE. Enrolment and dosing risk is retired; what remains is follow-up time and the analysis.\n- **2026-05-06 — FDA written alignment** under breakthrough designation on a single-arm, interim-driven BLA pathway. This is the structural asset; everything else in the story is downstream of it holding.\n\n## Bear Case\n\n- **The calendar is empty until H1 2027.** Reaffirmed 2026-08-11. Roughly three quarters separate the tape from the next company-specific binary. During that window the name trades on sector flow.\n- **Issuance into strength has been executed and the buyers are not yet paid.** The June deal priced at $6.00, upsized to $230M gross with the full underwriter option exercised. Share count moved to 325.3M. The 2026-08-14 close of $5.95 sits under the placement price. Until $6.00 is reclaimed and held on volume, the deal book is a supply source on strength.\n- **2026-08-11 — Q2 EPS $(0.13) versus $(0.12) consensus**, net loss $46.6M. Immaterial to the thesis, but it removes the \"beat-and-raise cadence\" argument entirely; there is no revenue line and no operating metric that improves quarter to quarter here.\n- **Structural regulatory risk is unresolved, not removed.** An open-label, single-arm design with n=17 and a novel primary endpoint leaves the agency room to require controlled data at the H1 2027 pathway discussion. The 2026-05-06 written alignment reduces that probability; it does not eliminate it, and the discussion has not happened.\n- **Sell-side targets are far above the tape.** Aggregator consensus in August 2026 clusters between roughly $10.80 and $13.25 depending on the panel (12–16 analysts, Strong Buy skew). That spread is a probability-weighted approval NPV; it does not generate a bid during a catalyst gap.\n- **Single-site, single-asset, single-indication.** Value concentrates in TSHA-102 and, from 2026-08-03, in one commercial manufacturing site.\n\n## Setup & Price Structure\n\nThe 2026-08-14 close of **$5.95** sits mid-range: **-14.8%** from the **$6.98** 52-week high (adjusted series), with **RSI(14) 57.2** and a **-0.2%** three-month return. Neither trend nor exhaustion — a consolidation that has absorbed a $230M placement without breaking.\n\nThe two levels that matter are both known to every holder. **$6.00** is the June 2026 placement price and the overhead reference; repeated weekly closes capped beneath it describe a book still working through supply. Below, the post-offering consolidation floor near **$5.25** is where digestion would cease to be digestion. A weekly close under that level would mean the market is repricing the asset rather than clearing the deal.\n\nPositioning observables, stated without a verdict: 325.3M shares outstanding after a June raise executed directly into the post-data high; a Strong Buy-skewed coverage cluster with targets roughly 1.8–2.2x the tape; no earnings date inside the next 30 days (the Q2 print elapsed 2026-08-11); no insider transactions surfaced in the recent filings window. The absence of an imminent print cuts both ways — no event risk, and no scheduled reason for new money to arrive.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-11-10 (est.)** — Q3 2026 results. Estimated from the 2026-08-11 Q2 cadence; not company-confirmed. The only tradeable content is whether H1 2027 interim timing and Q4 2026 PPQ completion survive intact.\n- Sector-level only: XBI direction and any AAV or Rett-program safety headline (NGNE is the direct read-across) drive the tape in the interim.\n\n## Elapsed catalysts\n\n- **No company-specific dated catalyst falls inside the 30 days from 2026-08-15.** The Q2 print (2026-08-11) and the 10-Q have both cleared. This is stated as a finding, not a placeholder. *(passed 11d ago)*\n- **Q4 2026 (guided, 2026-08-11)** — PPQ manufacturing completion. The CMC gate for the BLA. *(passed 15d ago)*\n- **H1 2027 (guided, 2026-08-11)** — REVEAL pivotal six-month interim topline **and** FDA feedback on the BLA submission pathway. The binary. *(passed 15d ago)*\n\n## What Would Change Our Mind\n\nThe structure that has to hold is the post-offering base — the zone that has absorbed the June placement since 2026-06-24. Losing it converts an orderly digestion into distribution, and the fundamental case cannot defend it because there is no dated company event to reprice against until 2027. Concretely: **a weekly close below $5.25** breaks that base.\n\nThree non-price conditions would change the read independently of the level:\n\n1. **A guidance slip at the Q3 update.** If the H1 2027 interim moves to 2H 2027, or Q4 2026 PPQ completion moves into 2027, the funded-runway argument stops compensating for the wait.\n2. **A regulatory shift.** Any language indicating the FDA wants randomized or sham-controlled data, or the removal of \"single-arm, interim-driven\" from the described pathway, breaks the 2026-05-06 alignment that the entire filing timeline rests on.\n3. **A safety event.** A treatment-related SAE, dose-limiting toxicity or neuroinflammation signal in the pivotal or ASPIRE follow-up would end the thesis outright rather than dent it — the clean record across 33 patients is what makes a 17-patient single-arm filing arguable.\n\nOn the upside, a volume-backed reclaim and hold of **$6.00** — clearing the placement price — would be the first evidence the deal book has been absorbed rather than merely parked.\n\n## Correlation Notes\n\n- **XBI / small-cap biotech beta is the dominant driver for the next two-plus quarters.** With no company-specific event dated before H1 2027, daily moves are mostly sector flow and rate sensitivity. A useful check: does the name make lower lows on days with no company news while XBI falls?\n- **NGNE (Neurogene) is the direct Rett read-across.** Its NGN-401 program shares the indication and the AAV delivery question; safety or efficacy headlines there transmit to TSHA sentiment without any TSHA news.\n- **AAV gene-therapy safety headlines sector-wide** are the main exogenous risk to a name whose whole case is a clean tolerability record.\n- **Catalent (Harmans, MD) is now a single-point supply dependency.** Catalent is not publicly traded, so the dependency shows up only in TSHA disclosure — any tech-transfer or capacity disclosure at the Q3 print carries more weight than it did before 2026-08-03.",
  "first_seen": "2026-04-20",
  "last_analyzed": "2026-08-15T12:15:56+00:00",
  "last_synthesized": "2026-08-15",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}